“Committed to making the difference”
AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).
Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.
Royalty Pharma - AiCuris
|Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (Letermovir) from AiCuris Anti-infective Cures GmbH|
Breakthrough Therapy Designation
|AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients|
Corona diagnostic support for NRW
|Together with state-run veterinary institutes in NRW AiCuris is involved in carrying out approximately 20,000 tests against SARS-CoV-2|